- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
PCSK9 Antibody / Proprotein Convertase Subtilisin Kexin 9 Antibody targets proprotein convertase subtilisin/kexin type 9 (PCSK9), a secreted protein that plays a central role in cholesterol homeostasis by regulating the abundance of low-density lipoprotein receptors (LDLR). PCSK9 is produced predominantly by hepatocytes and belongs to the subtilisin-like proprotein convertase family. Unlike many related proteases, mature PCSK9 primarily functions through protein interactions rather than conventional catalytic processing of extracellular substrates. Its ability to regulate LDLR availability makes it an important determinant of circulating low-density lipoprotein cholesterol (LDL-C) concentrations.
PCSK9 is synthesized as a precursor that undergoes autocatalytic cleavage within the endoplasmic reticulum. This processing generates a mature protein that remains associated with its inhibitory prodomain, a structural arrangement required for proper secretion. Following release into the circulation, PCSK9 binds the epidermal growth factor-like repeat A domain of LDLR. The resulting complex can be internalized through receptor-mediated endocytosis, after which PCSK9 promotes lysosomal degradation of LDLR rather than allowing efficient receptor recycling to the cell surface. Reduced LDLR abundance limits hepatic clearance of circulating LDL particles and contributes to increased plasma cholesterol concentrations.
PCSK9 expression is regulated by metabolic and transcriptional mechanisms, including sterol regulatory element-binding protein 2 (SREBP2). When intracellular cholesterol availability decreases, SREBP2 stimulates the expression of genes involved in cholesterol uptake and synthesis, including LDLR and PCSK9. This coordinated response creates a regulatory balance between increasing LDLR production and limiting receptor persistence. Additional influences on PCSK9 expression include hormonal signaling, nutritional conditions, and inflammatory pathways.
Genetic studies have established the importance of PCSK9 in cardiovascular disease. Gain-of-function variants can cause autosomal dominant hypercholesterolemia by increasing LDLR degradation, whereas loss-of-function variants are associated with reduced LDL-C concentrations and protection against coronary artery disease. These discoveries supported the development of PCSK9-targeted therapies, including monoclonal antibodies that interfere with PCSK9-LDLR binding and small interfering RNA approaches that reduce hepatic PCSK9 production. Beyond cholesterol regulation, PCSK9 continues to be investigated in relation to metabolic disorders, inflammation, and vascular biology. The PCSK9 Antibody provides a reagent for examining the expression and processing of this important regulator of lipoprotein metabolism.
Explore our Metabolism Antibodies collection for additional research antibodies targeting proteins involved in cholesterol homeostasis, lipoprotein metabolism, and cellular lipid regulation.
Optimal dilution of the PCSK9 Antibody / Proprotein Convertase Subtilisin Kexin 9 Antibody should be determined by the researcher.
A human recombinant protein (amino acids S153-Q344) was used as the immunogen for the PCSK9 antibody.
After reconstitution, the PCSK9 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.
PCSK9 protein antibody, Proprotein convertase 9 antibody, Proprotein convertase subtilisin/kexin type 9 antibody, Neural apoptosis-regulated convertase 1 antibody, NARC-1 antibody, PC9 antibody, Subtilisin-like proprotein convertase 9 antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.